Citations

Clear

387 citation(s) found for "Couch, Fergus".

Abstract 2779: Development and evaluation of a MIRAI 5-year risk model with a breast cancer polygenic risk score.
Scott, C, Kraft, Peter, Banerjee, Imon, Medero, Ramon Correa, Couch, Fergus J., Vachon, Celine M., Scott, Christopher G. , Banerjee, Imon , Correa, Ramón , Norman, Aaron D. , Couch, Fergus J. , Kerlikowske, Karla , Winham, Stacey J.

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 2779-2779

10.1158/1538-7445.am2026-2779 Get It

Abstract Artificial intelligence (AI)-scores estimated from digital mammograms predict future breast cancer (BC) risk. MIRAI is a deep learning BC risk model that provides a continuous 5-year risk of overall BC from four screening full field digital mammograms. Common germline genetic variation in the form of a polygenic risk score (BC-PRS) is associated with increased BC risk and may improve MIRAI’s 5-year risk prediction. Our goal was to develop an updated MIRAI 5-year risk model that incorporates the BC-PRS (MIRAI+PRS) and to evaluate its discriminatory accuracy and calibration for both overall and invasive BC compared to MIRAI alone. We developed the MIRAI+PRS model by multiplying each woman’s 5-year MIRAI risk estimate by their relative risk based on their BC-PRS relative to the population mean. We evaluated the models within the Mayo Clinic Biobank mammography cohort, comprised of 12,307 women without a prior history of BC; 176 invasive and 250 overall BC were diagnosed within 5 years. MIRAI was estimated on screening mammograms closest to enrollment but at least 6 months prior to BC. Discriminatory accuracy, assessed by C-statistic, was high and similar for MIRAI+PRS vs. MIRAI models, for overall BC and invasive BC (Table). Calibration assessed by observed to expected (O/E) ratios was also similar for MIRAI+PRS compared to MIRAI predictions for BC outcomes (Table), although there was improvement in decile-specific O/E ratios across the lowest risk deciles (<1.67%) for MIRAI+PRS. Calibration for invasive cancer was poor for MIRAI with or without PRS. In summary, the MIRAI+PRS risk model did not result in significant difference of discriminatory accuracy or overall calibration compared to the MIRAI model, but there was evidence for improved calibration for women with 5-year risk below 1.67%. For invasive BC, the model had poor calibration regardless of whether PRS was included, underscoring the importance of training AI models for BC outcomes that are associated with a clinical intervention. Citation Format: Christopher G. Scott, Peter Kraft, Imon Banerjee, Ramon Correa Medero, Aaron D. Norman, Fergus J. Couch, Karla Kerlikowske, Stacey J. Winham, Celine M. Vachon. Development and evaluation of a MIRAI 5-year risk model with a breast cancer polygenic risk score [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2779.
The Human Male Mammary Gland has Similar Epithelial Populations to Female but Distinct Composition and Transcriptional Properties
Ibañez-Rios, M. Iliana , Aalam, Syed Mohammed Musheer , Ritting, Megan L. , Jore, Ashlyn, Chaludia, Keyur, Emperumal, Chitra Priya , Jakub, James W, McLaughlin, Sarah A. , Degnim, Amy C, Boughey, Judy C. , Couch, Fergus J. , Sadanandam, Anguraj , Radisky, Derek, Knapp, David J.H.F., Degnim, Amy C. , Jakub, James W. , Boughey, JC , Couch, Fergus J. , Jakub, James W , Degnim, Amy C , Yadav, Siddhartha , Sadanandam, Anguraj , Sherman, Mark E , Radisky, Derek C , Knapp, David J H F , Kannan, Nagarajan , Musheer Aalam, Syed Mohammed , Yadav, Siddhartha , Sherman, Mark E. , Radisky, Derek C. , Knapp, David J. H. F. , Kannan, Nagarajan

Mayo Clinic

No container title available | March 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.03.27.714915 | PMID 41959192 Get It

ABSTRACT The normal adult male breast has not been characterized at single-cell resolution, leaving the cellular basis of male breast cancer (MBC) biology undefined. Here we present an integrated single-cell RNA sequencing atlas of the adult human breast comprising 174,471 cells from 17 donors (3 male, 14 female), including 18,117 male-derived cells. This revealed that the male breast retains all three epithelial populations, basal (BC), luminal progenitor (LP), and luminal committed cells (LC), but with an increase in LC at the expense of BC and LP across all three male donors. Male LC were distinguished from female by elevated ESR1 and PGR mRNA, enrichment of RNA processing and ribosome biogenesis programs, reduced inflammatory cytokine and growth factor signaling, elevated estradiol gene set enrichment scores, and higher inferred activity of developmental patterning transcription factors. This pattern was observed across differential expression, gene ontology, ligand profiling, and regulon-based analyses, and was not restricted to sex chromosome-linked gene expression. This is consistent with the near-universal estrogen receptor (ER) positivity that characterizes MBC clinically. This atlas provides the first cellular and transcriptional reference for the normal male breast and a resource for investigating sex differences in mammary biology, germline susceptibility variant interpretation, and modeling breast malignancies.
Performance of clinical breast cancer risk prediction models vs a mammography-based artificial intelligence risk model
Kaul, M., Scott, C., Wadzinske, Alena , Banerjee, Imon, Hursh, Dan, Norman, Aaron, Wu, Fang-Fang, Medero, Ramon Correa, Couch, Fergus, Pruthi, Sandhya , Olson, JA, Kerlikowske, Karla, Vachon, Celine M, Scott, Christopher G. , Couch, Fergus J. , Norman, Aaron D. , Banerjee, Imon , Correa, Ramón , Couch, Fergus J. , Kaul, Medha , Scott, Christopher , Banerjee, Imon , Norman, Aaron D , Correa-Medero, Ramon Luis , Kontos, Despina , McCarthy, Anne Marie , Winham, Stacey J , Kerlikowske, Karla M , Vachon, Celine M. , Pruthi, Sandhya , Hursh, Dan, Winham, Stacey J. , Kerlikowske, Karla

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 24, 2026 | Volume: 118 | Issue: 8 | Pages: 1485-1495

10.1093/jnci/djag083 | PMID 41885411 Get It

Abstract Background Artificial intelligence (AI)–based, mammography breast cancer risk prediction models show improved discriminatory accuracy relative to clinical risk models. However, data on their calibration are limited. This study compared model performance of 3 clinical breast cancer risk models: Gail, Tyrer–Cuzick v8, and Breast Cancer Surveillance Consortium v3 with the MIRAI AI-risk model. Methods Digital mammograms were ascertained from a screening mammography cohort of 12 308 women within the Mayo Clinic Biobank with 250 incident breast cancers (176 invasive) within 5 years. We predicted 5-year breast cancer risk, estimated discriminatory accuracy (C-index), and calibration (observed-to-expected ratio) of both overall and invasive breast cancer and compared estimates using bootstrapping approaches. Results MIRAI demonstrated similar or improved discriminatory accuracy of overall breast cancer (C-index = 0.71, 95% confidence interval [CI] = 0.68 to 0.74) and invasive breast cancer (C-index = 0.71, 95% CI = 0.67 to 0.75) compared with clinical models (overall breast cancer: C-index = 0.59-0.68; invasive breast cancer: C-index = 0.60-0.68). MIRAI’s calibration for risk of overall breast cancer (observed-to-expected ratio = 0.96, 95% CI = 0.85 to 1.08) was improved compared with Gail (observed-to-expected ratio = 1.22, 95% CI = 1.07 to 1.38) and Breast Cancer Surveillance Consortium (observed-to-expected ratio = 1.38, 95% CI = 1.22 to 1.56) but similar to TC with volumetric percent density and polygenic risk score (observed-to-expected ratio = 0.99, 95% CI = 0.87 to 1.13). However, for low-risk women (approximately 50%), MIRAI overestimated risk of overall breast cancer. MIRAI also overestimated risk of invasive breast cancer across the risk spectrum (observed-to-expected ratio = 0.68, 95% CI = 0.58 to 0.78), whereas clinical models had good calibration (observed-to-expected ratio = 0.86–0.99). Conclusion MIRAI demonstrated stronger discriminatory accuracy than clinical models for 5-year overall and invasive breast cancer risk prediction but overestimated risk for both breast cancer endpoints. AI-based risk models should consider discriminatory accuracy and calibration for invasive cancer before implementation.
Long-Term Survival in High-Grade Serous Ovarian Cancer Compared With the General US Population: A 30-Year Landmark Analysis
Vitis, Luigi Antonio De , Larson, Melissa C., Atkinson, Hunter J., Block, Matthew S. , CLIBY, W, Couch, Fergus J., Dowdy, Sean C., Glaser, Gretchen E., Goergen, Krista M., Goode, E., Gostout, Bobbie S., Hartmann, Lynn C., Heinzen, Ethan P. , Huang, Yajue, Jatoi, Aminah , Jones, Monica B., Karow, Katie J., Keeney, Gary L., Kumar, Amanika, Langstraat, Carrie L., Lee, Sun-Hee , Mariani, A., Ostby, Stuart A. , Peethambaram, Prema P. , Podratz, Karl C. , Shahi, Maryam , Sherman, M., Sommerfield, Marla Kay, Wall, Vonda M., Weroha, S. John, Hendrickson, Andrea E. Wahner , Maurer, Matthew J., Bakkum-Gamez, Jamie, Oberg, Ann L. , Cliby, William A. , Couch, Fergus J. , Larson, Melissa C. , Glaser, Gretchen , Couch, Fergus J. , De Vitis, Luigi A, Jones, Monica, Glaser, Gretchen , Larson, Melissa C , Cliby, William A , Atkinson, Hunter J., Dowdy, Sean C. , Hartmann, Lynn C. , Kumar, Amanika , Langstraat, Carrie , Sherman, Mark E. , Sommerfield, Marla-Kay, Swisher, Elizabeth M. , Wall, Vonda M., Maurer, Matthew J. , Kaufmann, Scott H. , Bakkum‐Gamez, Jamie N.

Mayo Clinic

JCO Oncology Advances | March 20, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1200/oa-25-00142 | PMID 41918500 Get It

PURPOSE To compare mortality risk among long-term survivors of high-grade serous ovarian cancer (HGSOC) with that of the general US population and to examine how mortality and recurrence trends have evolved under changing treatment approaches. MATERIALS AND METHODS This is a retrospective cohort study including patients with histologically confirmed HGSOC treated at a single referral cancer center from 1991 to 2022. Mortality risk, expressed as standardized mortality ratios (SMRs, ratio of observed deaths in the study population to expected deaths in an age-matched US population), was assessed at diagnosis and yearly on patients without events (disease persistence, recurrence, or death from any cause). RESULTS A total of 2,074 consecutive patients were included. The median follow-up was 12.5 years (IQR, 11.7-13.8). Most patients were stage III (1,396, 69.2%), 1,299 (62.8%) underwent primary cytoreductive surgery, and 1,688 (87.4%) received platinum-taxane as first-line therapy. At diagnosis, the mortality rate was 7.40 times higher than that in the general population (95% CI, 7.04 to 7.77). By 7 event-free years, the 95% CI for the SMR included 1 for the first time, and at 10 years, the SMR was 1.05 (95% CI, 0.72 to 1.49), indicating no statistically significant excess mortality compared with the general population. In those event-free at 10 years, the 5-year cumulative incidence of ovarian cancer–related deaths (8.2% [95% CI, 4.2 to 16.0]) was comparable with that of non–ovarian cancer–related deaths (6.3% [95% CI, 2.9 to 13.8]). CONCLUSION In this cohort, mortality risk steadily declined for patients who remained event-free, approaching that of the general population by 7 years after diagnosis. These results emphasize the importance of individualized, long-term follow-up to address both recurrence risk and survivorship needs.
Landscape of somatic genetic alterations and PAM50 intrinsic subtypes in breast cancer associated with germline pathogenic variants in DNA-repair genes
Yadav, Siddhartha , Reid, Sonya , Yilma, Binyam , Fragkogianni, Stamatina, Whisenant, Jennifer G. , Weidner, Anne , Rajagopal, Padma Sheila , Huang, Minxuan , Mauer, Elizabeth , Arafa, Ali T., Chao, Calvin, Antonarakis, Emmanuel S, Kurian, Allison, Couch, Fergus J, Pal, Tuya, Kurian, Allison W. , Mauer, Elizabeth , Arafa, Ali T. , Arafa, Ali , Teslow, Emily A , Antonarakis, Emmanuel S , Kurian, Allison W , Couch, Fergus J. , Pal, Tuya , Yadav, Siddhartha , Fragkogianni, Stamatina , Weidner, Anne , Chao, Calvin Y. , Teslow, Emily A. , Antonarakis, Emmanuel S. , Couch, Fergus J. , Pal, Tuya

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 11, 2026 | Volume: 118 | Issue: 8 | Pages: 1416-1424

10.1093/jnci/djag070 | PMID 41832987 Get It

Abstract Background The association of germline pathogenic and likely pathogenic variants (GPVs) in hereditary breast cancer genes with underlying tumor biology and clinical outcomes remains incompletely understood. This study characterized differences in somatic alterations and intrinsic subtypes between sporadic and hereditary breast cancers associated with GPVs in ATM, BRCA1, BRCA2, CHEK2, or PALB2. Methods This retrospective cohort study included women with breast cancer and an ATM, BRCA1, BRCA2, CHEK2, or PALB2 GPV who had undergone tumor sequencing and whole transcriptome RNA expression analysis. Clinicopathological features, intrinsic subtypes, somatic alterations, and survival were compared by GPV status and immunohistochemistry-defined subtype and to sporadic cases. All statistical significance tests were 2-sided. Results The 4988 women with breast cancer in this study included 98 BRCA1, 126 BRCA2, 74 PALB2, 54 ATM, and 83 CHEK2 GPVs. Compared with sporadic cases, hormone receptor–positive/(ERBB2) formerly HER2–negative tumors in BRCA1 GPVs were statistically significantly enriched for basal subtype (45.5% vs 11.4%; P < .001), while CHEK2 carriers had a higher prevalence of luminal A subtype (80.4% vs 60.3%; P = .006). In hormone receptor–positive/(ERBB2)-negative breast cancers, BRCA1 GPVs were enriched for TP53 alterations (84.6% vs 29.8%; q < 0.001), ATM GPVs with FGFR1 alterations (35.4% vs 12.7%; q = 0.04), and BRCA2 GPVs with APC alterations (10.1% vs 1.5%; q = 0.004). Conversely, BRCA2 GPVs were inversely associated with PIK3CA alterations (13.0% vs 34.1%; q = 0.005) and CHEK2 GPVs with TP53 alterations (8.0% vs 29.8%; q = 0.02). Conclusions The GPVs in BRCA1, BRCA2, ATM, CHEK2, and PALB2 are associated with distinct intrinsic breast cancer subtypes and somatic genomic alterations. These findings may enhance precision in risk stratification and guide personalized treatment strategies.
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2
Apostol, Adriana Ionelia , Gronwald, J., Cybulski, C., Kim, Raymond H. , Møller, P., Karlan, B., Bordeleau, Louise , Schrader, Intan , Cajal, Teresa Ramón y , Pal, Tuya, Eisen, Andrea, Singer, Christian F., Couch, Fergus J., Zakalik, Dana , Metcalfe, Kelly , Olopade, Olufunmilayo, Tung, Nadine, Fruscio, R, Foulkes, William D., Sun, P., Lubinski, J., Narod, Steven A., Sweet, Kevin , Elser, Christine , Panchal, Seema, Wiesner, Georgia L. , Armel, Susan, Steele, Linda, Serfas, Kim, Cullinane, Carey A., Reilly, Robert E., Mercer, L J, Dungan, Jeffrey R., Cohen, Stephanie, Neuhausen, Susan, Sun, Sophie, Blum, Joanne L., Stempa, Klaudia , Graham, Tracy Ann, Seca, Marta , Marchette, Martina Delle , Dell'Oro, Cristina, Alfonso, Rosa Moreno, Lopez, Consol, Cusco, Francesco, Karlan, Beth Y. , Schrader, Kasmintan A. , Eisen, Andrea , Apostol, Adriana I , Cybulski, Cezary , Karlan, Beth Y , Ramón Y Cajal, Teresa , Singer, Christian F , Couch, Fergus J. , Olopade, Olufunmilayo I , Tung, Nadine , Fruscio, Robert , Foulkes, William D , Aeilts, Amber M , Lubinski, Jan , Narod, Steven A , Kotsopoulos, Joanne , Metcalfe, Kelly A , Eisen, Andrea , Bordeleau, Louise , Kim, Raymond H , Cybulski, Cezary , Møller, Pål , Pal, Tuya , Singer, Christian F. , Couch, Fergus J. , Olopade, Olufunmilayo I. , Tung, Nadine , Foulkes, William D. , Aeilts, Amber M. , Lubiński, Jan , Narod, Steven A. , Kotsopoulos, Joanne , Steele, Linda, Saal, Howard M. , Rayson, Daniel , Mercer, Leanne, Cohen, Stephanie, Neuhausen, Susan L, Senter, Leigha , Blum, Joanne Lorraine , Negri, Serena , Dell’Oro, Cristina, Inzoli, Alessandra , Alfonso, Rosa

Mayo Clinic

Journal of Clinical Oncology | February 28, 2026 | Volume: 44 | Issue: 10 | Pages: 883-892

10.1200/jco-25-01648 | PMID 41762747 Get It

PURPOSE BRCA carriers face high risks of developing both breast and ovarian/fallopian tube cancers (hereafter referred to as ovarian ). Among BRCA carriers with ovarian cancer, it is not clear whether the risk of breast cancer is sufficiently high that risk-reducing mastectomy should be offered. This study aimed to assess the risk of breast cancer BRCA carriers after a diagnosis of ovarian cancer. METHODS We included women with a pathogenic/likely pathogenic variant in BRCA1 or BRCA2 , a diagnosis of ovarian cancer, and no other cancer history and no risk-reducing bilateral mastectomy. Women were followed for incident breast cancer from the date of ovarian cancer diagnosis or the date of baseline questionnaire, whichever came last. The 5-, 10-, and 15-year cumulative risks of breast cancer were compared for women with ovarian cancer and an age-matched set of control women without ovarian cancer. RESULTS A total of 960 participants with ovarian cancer were identified (814 BRCA1 and 146 BRCA2 carriers). After a mean follow-up of 4.9 years, 41 women (4.3%) developed breast cancer, at a mean age at diagnosis of 57.5 years (range, 39-74). Actuarial cumulative breast cancer risks after ovarian cancer were 4.4%, 8.9%, and 11.5% at 5, 10, and 15 years, respectively. Only three breast cancer–related deaths occurred. Among 741 age-matched BRCA carriers without ovarian cancer, actuarial cumulative risks of breast cancer were 20.9%, 38.6%, and 47.2% at 5, 10, and 15 years, respectively. The hazard ratio for breast cancer, after an ovarian cancer diagnosis, compared with no ovarian cancer, was 0.18 ([95% CI, 0.12 to 0.27]; P < .0001). CONCLUSION After ovarian cancer, BRCA carriers have a relatively low risk of breast cancer. Risk-reducing mastectomy should not be recommended routinely, but might be considered for long-term survivors. Magnetic resonance imaging surveillance and/or mammography is a realistic alternative.
Factors associated with and patterns of alcohol intake in late survivorship for breast cancer survivors
Rajput, Sanjna , Vierkant, Robert A., Olson, Kayleigh N., Larson, Nicole L. , Stan, Daniela L., Mussallem, Dawn M. , D’Andre, Stacy D. , Couch, F, Olson, Janet E., O’Sullivan, Ciara C. , Ruddy, Kathryn, Vierkant, Robert A., Couch, Fergus J. , Olson, Janet E. , Ruddy, Kathryn J.

Mayo Clinic

No container title available | January 29, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8492613/v1 | PMID 41646397 Get It

Abstract Purpose To evaluate alcohol intake trends and identify demographic, clinical, lifestyle and socioeconomic factors associated with alcohol consumption in late survivorship among breast cancer survivors. Methods Individuals diagnosed with stage 0–3 breast cancer enrolled in the Mayo Clinic Breast Disease registry between 2014 to 2022 reported their average weekly alcohol intake at baseline (time of diagnosis) and at approximately four years post-diagnosis. Alcohol intake was divided into four categories and cross-sectional associations with demographic, clinical, and lifestyle factors were examined using Monte Carlo-based Fisher exact tests and multivariable multinomial logistic regression. Changes in alcohol consumption from baseline to Year 4 were evaluated using Bowker’s test of symmetry and multinomial models. Results Among 719 participants, alcohol intake 4 years post diagnosis closely resembled baseline patterns, with 30.2% of patients reporting no alcohol use and 48.8% of patients consuming 1–4 drinks per week. Younger age and current smoking status were strongly associated with higher intake at Year 4. Exercise and better physical health were associated with higher alcohol intake in univariable models, however not in adjusted models. From time of diagnosis to Year 4, 15.6% of patients decreased their alcohol intake, 10.2% increased alcohol intake, and 74.3% reported no change. Higher levels of mild intensity exercise were associated with an elevation in alcohol intake over time. Conclusion Alcohol consumption remained stable in late survivorship, in contrast to the initial decline in alcohol use during early survivorship seen in this cohort. Younger age and smoking were key associations with higher alcohol intake.
Dual FAK and EPHA2 targeting by brigatinib tackles PARP inhibitor adaptive survival response in high-grade serous ovarian cancer
Duffield, Julie R. , Hou, Xiaonan, Wilson, Benjamin, Prasad, Anjali , McKeon-Makki, Iman K. , Huehls, Amelia M. , Wu, Xinyan, Correia, Cristina , Larson, Melissa C., Couch, Fergus J., Öberg, Ann, Kaufmann, S., Karnitz, Larry M., Weroha, S. John, Kanakkanthara, Arun , Kaufmann, Scott H. , Weroha, S. John , Couch, Fergus J. , Larson, Melissa C. , Wu, Xinyan , Couch, Fergus J. , Hou, Xiaonan , Wilson, Benjamin W, Wu, Xinyan , Larson, Melissa C , Oberg, Ann L , Kaufmann, Scott H , Weroha, S John , Correia, Cristina

Mayo Clinic

Science Translational Medicine | January 14, 2026 | Volume: 18 | Issue: 832 | Pages: No page available

10.1126/scitranslmed.adt8706 | PMID 41533776 Get It

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) are an important therapy for high-grade serous ovarian cancer (HGSOC). However, PARPi resistance frequently emerges, necessitating previously unrecognized approaches to improve HGSOC responses. Here, we showed that the anaplastic lymphoma kinase (ALK) inhibitor brigatinib enhances PARPi activity in HGSOC cells by disrupting an adaptive survival mechanism orchestrated by Fos-related antigen 1 (FRA1) in response to PARPi. This effect of brigatinib occurred through an ALK-independent pathway, wherein brigatinib induced a dual blockade of focal adhesion kinase (FAK) and EPH receptor A2 (EPHA2) tyrosine kinases, leading to the suppression of protein kinase B (Akt) and extracellular-regulated kinase (ERK) signaling accompanied by disruption of a phosphorylation event crucial for FRA1 protein stability. Moreover, in HGSOC patient-derived xenograft (PDX) models, brigatinib and PARPi combination therapy induced tumor regression and improved overall survival compared with PARPi alone, particularly in models with high FAK and EPHA2. These findings support dual targeting of FAK and EPHA2 as a strategy to achieve effective and durable PARPi responses and identify a promising biomarker-based combinatorial approach using brigatinib and PARPi for HGSOC, particularly the subset characterized by high FAK and EPHA2.
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in BRCA1
Apostol, Adriana Ionelia , Metcalfe, Kelly , Jorgji, Dimitri , Cybulski, Cezary , Gronwald, Jacek , Lubiński, Jan , Møller, Pål , Kim, Raymond H. , Aeilts, Amber M. , Cajal, Teresa Ramón y , Pal, Tuya , Bordeleau, Louise , Karlan, Beth Y. , Couch, Fergus J., Zakalik, Dana , Fruscio, Robert , Tung, Nadine, Sun, Ping, Monteiro, Álvaro N.A. , Narod, Steven A. , Akbari, Mohammad R. , Apostol, Adriana I , Jorgji, Dimitri , Cybulski, Cezary , Gronwald, Jacek , Lubinski, Jan , Kim, Raymond H , Aeilts, Amber M , Ramón Y Cajal, Teresa , Pal, Tuya , Karlan, Beth Y , Fruscio, Robert , Monteiro, Alvaro N , Narod, Steven A , Metcalfe, Kelly A , Bordeleau, Louise , Kotsopoulos, Joanne , Singer, Christian F. , Foulkes, William D. , Sun, Ping

Mayo Clinic

Current Oncology | December 15, 2025 | Volume: 32 | Issue: 12 | Pages: 705

10.3390/curroncol32120705 | PMID 41440233 Get It

Background: Carriers of a pathogenic variant (PV) in BRCA1 face a high risk of breast cancer. This study estimated the risk of developing breast cancer according to mutation type and location. Methods: BRCA1 carriers with no personal history of breast cancer or bilateral mastectomy were included. Detailed information on clinical and family history was collected by questionnaire. Survival analysis was used to estimate 15-year cumulative risk according to PV type and location. Results: A total of 3677 BRCA1 carriers were followed for a mean of 7.2 years (range 0.1–15.0 years); 481 incident breast cancers were documented. Overall, the 15-year cumulative incidence was 25%. Risk estimates varied by exon, ranging from 9% (exon 21) to 19% (exon 12) to 36% (exon 15); however, strata were small. Carriers of four founder mutations common in Eastern Europe (c.5263_5264insC, c.181T > G, c.66_67delAG and c.4034delA) experienced a lower-than-expected cancer risk (15.9–24.4%) compared to other PVs (28.8%) (p = 0.02). Conclusions: Although our data suggests some variability in penetrance based on specific BRCA1 PV, this was based on a large number of founder mutations. Breast cancer management strategies should continue to be based on comprehensive risk assessment.
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2
Kotsopoulos, Joanne , Seca, Marta , Gronwald, Jacek, Møller, Pål , Kim, Raymond H. , Singer, Christian F., Karlan, Beth Y. , Aeilts, Amber M. , Cajal, Teresa Ramón y , Eisen, Andrea , Bordeleau, Louise , Tung, Nadine, Neuhausen, Susan L., Zakalik, Dana , Olopade, Olufunmilayo, Metcalfe, Kelly , Sun, Ping, Narod, Steven A., Olopade, Olufunmilayo I. , Singer, Christian F. , Huzarski, Tomasz , Kim, Raymond H , Singer, Christian F , Karlan, Beth Y , Aeilts, Amber M , Ramón Y Cajal, Teresa , Eisen, Andrea , Bordeleau, Louise , Foulkes, William D , Tung, Nadine , Couch, Fergus J. , Neuhausen, Susan L. , Cybulski, Cezary , Olopade, Olufunmilayo I , Fruscio, Robert , Lubinski, Jan , Narod, Steven A , Metcalfe, Kelly A , Kotsopoulos, Joanne , Huzarski, Tomasz , Pal, Tuya , Foulkes, William D. , Tung, Nadine , Couch, Fergus J. , Cybulski, Cezary , Fruscio, Robert , Lubiński, Jan , Narod, Steven A.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | December 13, 2025 | Volume: 118 | Issue: 5 | Pages: 856-864

10.1093/jnci/djaf363 | PMID 41403285 Get It

Abstract Background Women with a pathogenic variant in BRCA1 or BRCA2 are at high risk of developing ovarian cancer, and it is often recommended that they undergo bilateral salpingo-oophorectomy at an early age, resulting in surgical menopause. Menopausal hormone replacement therapy (HRT) is an effective way to mitigate the adverse outcomes of early menopause; however, the safety of menopausal HRT on breast cancer risk in this population has not been established. Methods We conducted a prospective matched analysis of HRT use following menopause and breast cancer risk in BRCA carriers. Women who initiated HRT were matched one-to-one with women who had not initiated menopausal HRT by gene, year of birth, and age at menopause, resulting in 676 matched pairs. Menopausal HRT use collected by questionnaire included formulation and mode of administration. Results After a mean of 5.6 years, there were 87 (12.9%) incident breast cancer cases in the 676 exposed women and 128 (18.9%) cases in the 676 unexposed women (P = .002). Compared with unexposed matched control individuals, women who used estrogen alone experienced a statistically significantly decreased risk of breast cancer (hazard ratio = 0.37, 95% CI = 0.24 to 0.57). No protective or adverse effect was associated with the use of estrogen plus progestogen (hazard ratio = 0.94, 95% CI = 0.54 to 1.63). Conclusions Our findings suggest no substantial increase in the risk of breast cancer in BRCA carriers with the use of HRT and that estrogen alone might be protective.